Page 85 - HIV/AIDS Guidelines

55. GatheJC,Jr.,IveP,WoodR,etal.SOLO:48-weekefficacyandsafetycomparisonofonce-dailyfosamprenavir
/ritonavirversustwice-dailynelfinavirinnaiveHIV-1-infectedpatients.AIDS.Jul232004;18(11):1529-1537.
56. SmithKY,WeinbergWG,DejesusE,etal.Fosamprenaviroratazanavironcedailyboostedwithritonavir100mg,plus
tenofovir/emtricitabine,fortheinitialtreatmentofHIVinfection:48-weekresultsofALERT.AIDS Res Ther. 2008;5:5.
57. WalmsleyS,BernsteinB,KingM,etal.Lopinavir-ritonavirversusnelfinavirfortheinitialtreatmentofHIVinfection.N
Engl J Med.Jun272002;346(26):2039-2046.
58. MurphyRL,daSilvaBA,HicksCB,etal.Seven-yearefficacyofalopinavir/ritonavir-basedregimeninantiretroviral-
naiveHIV-1-infectedpatients.HIV Clin Trials.Jan-Feb2008;9(1):1-10.
59. EronJJ,FeinbergJ,KesslerHA,etal.Once-dailyversustwice-dailylopinavir/ritonavirinantiretroviral-naiveHIV-
positivepatients:a48-weekrandomizedclinicaltrial.J Infect Dis.Jan152004;189(2):265-272.
60. MolinaJM,PodsadeckiTJ,JohnsonMA,etal.Alopinavir/ritonavir-basedonce-dailyregimenresultsinbetter
complianceandisnon-inferiortoatwice-dailyregimenthrough96weeks.AIDS Res Hum Retroviruses.Dec
2007;23(12):1505-1514.
61. GatheJ,daSilvaBA,CohenDE,etal.Aonce-dailylopinavir/ritonavir-basedregimenisnoninferiortotwice-daily
dosingandresultsinsimilarsafetyandtolerabilityinantiretroviral-naivesubjectsthrough48weeks.J Acquir Immune
Defic Syndr.Apr152009;50(5):474-481.
62. MurphyRL,SanneI,CahnP,etal.Dose-ranging,randomized,clinicaltrialofatazanavirwithlamivudineandstavudine
inantiretroviral-naivesubjects:48-weekresults.AIDS.Dec52003;17(18):2603-2614.

63. SanneI,PilieroP,SquiresK,ThiryA,SchnittmanS.Resultsofaphase2clinicaltrialat48weeks(AI424-007):adose-
ranging,safety,andefficacycomparativetrialofatazanaviratthreedosesincombinationwithdidanosineandstavudine
inantiretroviral-naivesubjects.J Acquir Immune Defic Syndr.Jan12003;32(1):18-29.
64. WalmsleyS,AvihingsanonA,SlimJ,etal.Gemini:anoninferioritystudyofsaquinavir/ritonavirversus
lopinavir/ritonavirasinitialHIV-1therapyinadults. J Acquir Immune Defic Syndr.Apr12009;50(4):367-374.
65. YoungB,VanigT,DejesusE,etal.Apilotstudyofabacavir/lamivudineandraltegravirinantiretroviral-naiveHIV-1-
infectedpatients:48-weekresultsoftheSHIELDtrial.HIV Clin Trials.Sep-Oct2010;11(5):260-269.
66. FoodandDrugAdministration.Isentress(packageinsert)
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022145s018lbl.pdf.AccessedFebruary19,2012.
67. HeeraJ,IveP,BotesM,etal.TheMERITstudyofmaravirocinantiretroviral-naivepatientswithR5HIV-1:96-weeks
results.Paperpresentedat:5thInternationalAIDSSocietyConferenceonHIVPathogenesis,Treatment,andPrevention;
July19-22,2009;CapeTown,SouthAfrica.
68. Ait-KhaledM,StoneC,AmphlettG,etal.M184Visassociatedwithalowincidenceofthymidineanaloguemutations
andlowphenotypicresistancetozidovudineandstavudine.AIDS.Aug162002;16(12):1686-1689.
69. ArribasJR,PozniakAL,GallantJE,etal.Tenofovirdisoproxilfumarate,emtricitabine,andefavirenzcomparedwith
zidovudine/lamivudineandefavirenzintreatment-naivepatients:144-weekanalysis.J Acquir Immune Defic Syndr. Jan1
2008;47(1):74-78.
70. SaxPE,TierneyC,CollierAC,etal.Abacavir-lamivudineversustenofovir-emtricitabineforinitialHIV-1therapy.N
Engl J Med.Dec32009;361(23):2230-2240.
71. SmithKY,PatelP,FineD,etal.Randomized,double-blind,placebo-matched,multicentertrialofabacavir/lamivudineor
tenofovir/emtricitabinewithlopinavir/ritonavirforinitialHIVtreatment.AIDS.Jul312009;23(12):1547-1556.
72. ZimmermannAE,PizzoferratoT,BedfordJ,MorrisA,HoffmanR,BradenG.Tenofovir-associatedacuteandchronic
kidneydisease:acaseofmultipledruginteractions.Clin Infect Dis.Jan152006;42(2):283-290.
73. KarrasA,LafaurieM,FurcoA,etal.Tenofovir-relatednephrotoxicityinhumanimmunodeficiencyvirus-infected
patients:threecasesofrenalfailure,Fanconisyndrome,andnephrogenicdiabetesinsipidus.Clin Infect Dis.Apr15
2003;36(8):1070-1073.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents F-24

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.